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arget Populations in Allogeneic Hematopoietic
ell Transplantation for Autoimmune Diseases—
Workshop Accompanying: Cellular Therapy for
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tAfter our recent discussion of feasibility of alloge-
eic hematopoietic stem cell transplantation for auto-
mmune disease [1], important questions remained as
o the patient populations that are most appropriate
or such clinical trials. To consider the problem of
atient selection further, many of the same interna-
ional group of autoimmune disease experts and he-
atopoietic cell transplantation (HCT) physicians
et as a workshop in Newport Beach, CA, in October
005.
The group reached agreement on the following
oints.
1. Allogeneic HCT offers the potential to effect
emission and/or cure of refractory autoimmune dis-
ases including multiple sclerosis, systemic sclerosis,
nd systemic lupus erythematosus, as suggested by
ase reports and follow-up of patients with autoim-
une disease who received this therapy for another
rimary indication. In addition, for acquired aplastic
nemia, considered by many to have an autoimmune
tiology [2], allogeneic HCT is the treatment of
hoice for many patients who have an HLA-matched
ibling donor [3,4]. A signiﬁcant number of patients
ith severe autoimmune disease failed to respond to
onventional therapies and none of these are curative.
tudies of high-dose immunosuppressive/immune ab-
ative therapy with autologous HCT are currently
nderway in the United States and Europe, but several
ears will be required for follow-up to evaluate long-
erm efﬁcacy.
2. To obtain experience in allogeneic HCT for
Sponsored by the Bernie Marcus Foundation and the City of Hope
ational Medical Center, in Collaboration with NIAID, NCI,hULAR, and EBMT; Newport Beach, California; October 7, 2005.
88utoimmune disease that is scientiﬁcally well founded
nd maximally informative, it would be desirable to
nroll patients in studies at a time during their disease
ourse when the disorder is most likely to respond to
CT and who are optimal transplantation candidates.
tatus of the autoimmune disease (HCT early in the
isease might provide a chance for cure of the disease
nd prevention of organ damage caused by the dis-
ase), comorbidities (major organ dysfunction would
onstitute a risk for HCT), motivation, and type of
onor (an HLA-matched sibling would be preferred)
hould be considered. Patient age theoretically could
lso be important due to better preserved thymic tol-
rance acquisition pathways [5], but this notion needs
o be proven in HCT clinical trials. Classically, exper-
mental therapies such as HCT, with measurable risk
f morbidity and mortality, have been provided ini-
ially to patients who had late disease and no other
ptions for therapy. However, transplantation may
ot improve the clinical course for patients with au-
oimmune disease that is already very advanced. Such
atients might be “cured” of autoimmune disease by
CT but achieve no therapeutic beneﬁt due to failure
o prevent irreversible organ damage and end-stage
rgan failure caused by the autoimmune disease. Fur-
her, such patients may have multiple comorbidities
nd thus be at high risk for complications of HCT.
3. Current autologous HCT protocols in multiple
clerosis target those patients who have early relapsing
emitting disease with features indicating high risk for
volution to secondary progressive disease. A more
ccessible and practical population for pilot studies of
llogeneic HCT for multiple sclerosis might include
hose patients who are in the process of developing or
ave just developed secondary progressive disease. For
s
s
o
t
d
r
g
a
s
p
n
b
w
r
o
r
a
r
c
p
r
H
a
o
“
d
e
s
s
g
i
t
c
s
w
o
A
C
o
a
(
R
o
A
D
S
R
D
A
b
f
L
s
r
m
H
D
f
A
P
N
c
p
K
W
M
N
S
D
M
t
w
H
P
O
o
t
C
U
M
D
o
s
E
N
c
E
d
f
K
p
M
a
w
R
1
Letter to the Editor
Bystemic sclerosis, the ideal group would have aggres-
ive cardiac/pulmonary and/or renal disease predictive
f 50% survival at 5 years. Among patients with lupus,
he target group for HCT should have progressive
isease and/or involvement of a vital organ that is
esistant to 1 major line of therapy. While autolo-
ous protocols continue to enroll, it would be desir-
ble to specify noncompeting entry criteria for pilot
tudies of allogeneic HCT. A reasonable option in
atient selection for phase I/II pilot studies of alloge-
eic transplantation for autoimmune diseases would
e those with aggressive disease and poor prognosis
ho are unable to tolerate the high-dose preparative
egimens commonly used for autologous HCT. Many
f these patients would be suitable candidates for the
educed intensity or nonmyeloablative regimens of
llogeneic HCT, which also have the advantage of
educed treatment-related morbidity and mortality
ompared with conventional regimens [6]. In future
hase II studies, it may be informative to prospectively
andomize subjects to either autologous or allogeneic
CT.
4. When developing end points for clinical trials of
llogeneic HCT for autoimmune disease, the concept
f “extended remission” off immunosuppression and
cure” of disease should be considered because the
eﬁnition of beneﬁt may vary depending on the dis-
ase and type of patients who are enrolled. Toxicity
hould be monitored as a stopping rule.
In closing, we note that when developing patient
election criteria and evaluating risk/beneﬁt for allo-
eneic transplantation for nonmalignant indications
ncluding autoimmune diseases, despite advances in
ransplantation in recent years, many of the basic
onsiderations remain the same [7]. If successful, these
tudies of allogeneic HCT for autoimmune disease
ill provide an alternative for care of patients with
therwise very limited or no options.
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epartment of Medicine, University of California Los
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rogramme, Department of Medicine, University of
ttawa, Ottawa, Canada; Stephen J. Forman, Division
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A; Alois Gratwohl, Department of Hematology,
niversity Hospital Basel, Basel, Switzerland; Edwin
. Horwitz, Division of Stem Cell Transplantation,
ivision of Experimental Hematology, Department
f Hematology-Oncology, St. Jude Children’s Re-
earch Hospital, Memphis, TN; Steven Z. Pavletic,
xperimental Transplantation and Immunology Branch,
ational Cancer Institute, NIH, Bethesda, MD; Ric-
ardo Saccardi, Bone Marrow Transplant Unit, UO
matologia, Policlinico Careggi, Florence, Italy; Ju-
ith A. Shizuru, Bone Marrow Transplantation, Stan-
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eith M. Sullivan, Division of Cellular Therapy, De-
artment of Internal Medicine, Duke University
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